NCT03682731 is a clinical trial in Erythropoietic Protoporphyria, sponsored by Bispebjerg Hospital.

Who is sponsoring NCT03682731?

NCT03682731 is sponsored by Bispebjerg Hospital.

What condition does NCT03682731 study?

NCT03682731 studies Erythropoietic Protoporphyria.

Is NCT03682731 still recruiting?

NCT03682731 is currently completed. Last updated 2 October 2018.

Last reviewed 2018-10-02 · How we verify

NCT03682731

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria

Completed Last updated 2 October 2018

What this trial tests

trial in Erythropoietic Protoporphyria in 14 participants. Completed in 1 August 2017.

Timeline

1 April 2017

Primary endpoint
1 August 2017

1 August 2017

Quick facts

Lead sponsor	Bispebjerg Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	14
Start date	1 April 2017
Primary completion	1 August 2017
Estimated completion	1 August 2017
Sites	2 locations across Denmark

Conditions studied

Erythropoietic Protoporphyria — all drugs for Erythropoietic Protoporphyria →

Sponsor

Bispebjerg Hospital

Who can join

12 and older, any sex, with Erythropoietic Protoporphyria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Erythropoietic protoporphyria (EPP) is characterized by development of painful skin symptoms upon exposure to visible light dye to accumulation of the photoactive substance protoporphyrin IX (PpIX) in the skin.This study aimed to quantify the actual light exposure of patients with EPP during everyday life. The investigators further aimed to establish the associations between symptoms and light exposure, use of protective clothes, and erythrocyte PpIX concentration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bispebjerg Hospital trials

Trials by the same sponsor.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03682731 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
Last refreshed: 2 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing